Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
13,253
archived clinical trials in
Arthritis

A Synovial Biopsy Study of JNJ-38518168 in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Synovial Biopsy Study of JNJ-38518168 in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated:  4/11/2014
Clinical Research Facility
mi
from
La Jolla, CA
A Synovial Biopsy Study of JNJ-38518168 in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Synovial Biopsy Study of JNJ-38518168 in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated: 4/11/2014
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Synovial Biopsy Study of JNJ-38518168 in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Synovial Biopsy Study of JNJ-38518168 in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated:  4/11/2014
Clinical Research Facility
mi
from
Frederick, MD
A Synovial Biopsy Study of JNJ-38518168 in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Synovial Biopsy Study of JNJ-38518168 in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated: 4/11/2014
Clinical Research Facility
mi
from
Frederick, MD
Click here to add this to my saved trials
A Synovial Biopsy Study of JNJ-38518168 in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Synovial Biopsy Study of JNJ-38518168 in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated:  4/11/2014
Clinical Research Facility
mi
from
Mesquite, TX
A Synovial Biopsy Study of JNJ-38518168 in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Synovial Biopsy Study of JNJ-38518168 in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy
Status: Enrolling
Updated: 4/11/2014
Clinical Research Facility
mi
from
Mesquite, TX
Click here to add this to my saved trials
Autoantibodies to Gastric Parietal Cells in Rheumatoid Arthritis Patients
Presence of Autoantibodies to Gastric Parietal Cells and Subsequent Vitamin B12 Deficiency in Rheumatoid Arthritis Patients
Status: Enrolling
Updated:  5/13/2014
Keesler Medical Center
mi
from
Keesler AFB, MS
Autoantibodies to Gastric Parietal Cells in Rheumatoid Arthritis Patients
Presence of Autoantibodies to Gastric Parietal Cells and Subsequent Vitamin B12 Deficiency in Rheumatoid Arthritis Patients
Status: Enrolling
Updated: 5/13/2014
Keesler Medical Center
mi
from
Keesler AFB, MS
Click here to add this to my saved trials
INCB047986 in Rheumatoid Arthritis
A Double-Blind, Placebo-Controlled Study Exploring the Safety, Tolerability, and Efficacy of a 28-Day Course of INCB047986 in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated:  5/28/2014
Clinical Research Facility
mi
from
Frederick, MD
INCB047986 in Rheumatoid Arthritis
A Double-Blind, Placebo-Controlled Study Exploring the Safety, Tolerability, and Efficacy of a 28-Day Course of INCB047986 in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated: 5/28/2014
Clinical Research Facility
mi
from
Frederick, MD
Click here to add this to my saved trials
INCB047986 in Rheumatoid Arthritis
A Double-Blind, Placebo-Controlled Study Exploring the Safety, Tolerability, and Efficacy of a 28-Day Course of INCB047986 in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated:  5/28/2014
Clinical Research Facility
mi
from
Oklahoma City, OK
INCB047986 in Rheumatoid Arthritis
A Double-Blind, Placebo-Controlled Study Exploring the Safety, Tolerability, and Efficacy of a 28-Day Course of INCB047986 in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated: 5/28/2014
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
INCB047986 in Rheumatoid Arthritis
A Double-Blind, Placebo-Controlled Study Exploring the Safety, Tolerability, and Efficacy of a 28-Day Course of INCB047986 in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated:  5/28/2014
Clinical Research Facility
mi
from
Austin, TX
INCB047986 in Rheumatoid Arthritis
A Double-Blind, Placebo-Controlled Study Exploring the Safety, Tolerability, and Efficacy of a 28-Day Course of INCB047986 in Subjects With Active Rheumatoid Arthritis
Status: Enrolling
Updated: 5/28/2014
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
mi
from
Birmingham, AL
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
mi
from
Orange, CA
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
mi
from
Orange, CA
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
mi
from
DeLand, FL
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
mi
from
DeLand, FL
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
mi
from
Edgewater, FL
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
mi
from
Edgewater, FL
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
mi
from
Miami Lakes, FL
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
mi
from
Miami Lakes, FL
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
mi
from
Miami, FL
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
mi
from
Granger, IN
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
mi
from
Granger, IN
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
mi
from
Charlotte, NC
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
mi
from
Charlotte, NC
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
mi
from
Cinicinnati, OH
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
mi
from
Cinicinnati, OH
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
mi
from
Austin, TX
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
mi
from
Carrollton, TX
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
mi
from
Carrollton, TX
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
mi
from
Channelview, TX
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
mi
from
Channelview, TX
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
mi
from
Dallas, TX
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
mi
from
Houston, TX
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
mi
from
Mesquite, TX
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
mi
from
Mesquite, TX
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
mi
from
Plano, TX
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
mi
from
Plano, TX
Click here to add this to my saved trials
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated:  7/8/2014
Clinical Research Facility
mi
from
San Antonio, TX
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
Status: Enrolling
Updated: 7/8/2014
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Real Time 3D Imaging and Surrogate Bone Model
Comparison of Acetabular Shell Position Using 3D Planning vs. Standard Preoperative Planning: A Randomized Clinical Trial
Status: Enrolling
Updated:  7/29/2014
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Real Time 3D Imaging and Surrogate Bone Model
Comparison of Acetabular Shell Position Using 3D Planning vs. Standard Preoperative Planning: A Randomized Clinical Trial
Status: Enrolling
Updated: 7/29/2014
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Synvisc-One for Younger, Active Patients With Osteoarthritis
Long-Term Management of "Younger, Active" Patients With Pain From Early Knee Osteoarthritis With Synvisc-One (Hylan G-F 20)
Status: Enrolling
Updated:  8/4/2014
University of California
mi
from
San Francisco, CA
Synvisc-One for Younger, Active Patients With Osteoarthritis
Long-Term Management of "Younger, Active" Patients With Pain From Early Knee Osteoarthritis With Synvisc-One (Hylan G-F 20)
Status: Enrolling
Updated: 8/4/2014
University of California
mi
from
San Francisco, CA
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
mi
from
Mesa, AZ
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
mi
from
Mesa, AZ
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
mi
from
Scottsdale, AZ
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
mi
from
Hot Springs, AR
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
mi
from
Hot Springs, AR
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
mi
from
Covina, CA
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
mi
from
Covina, CA
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
mi
from
La Jolla, CA
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
mi
from
Long Beach, CA
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
mi
from
Long Beach, CA
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
mi
from
Los Angeles, CA
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
mi
from
Palo Alto, CA
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
mi
from
Upland, CA
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
mi
from
Upland, CA
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
mi
from
Hamden, CT
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
mi
from
Hamden, CT
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
mi
from
Lewes, DE
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
mi
from
Lewes, DE
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
mi
from
Debary, FL
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
mi
from
Debary, FL
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
mi
from
Jupiter, FL
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
mi
from
Jupiter, FL
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
mi
from
Tampa, FL
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
mi
from
Idaho Falls, ID
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
mi
from
Idaho Falls, ID
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
mi
from
Moline, IL
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
mi
from
Moline, IL
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
mi
from
Springfield, IL
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
mi
from
Springfield, IL
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
mi
from
Cedar Rapids, IA
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
mi
from
Cedar Rapids, IA
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
mi
from
Kansas City, KA
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
mi
from
Kansas City, KA
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
mi
from
St. Clair Shores, MI
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
mi
from
St. Clair Shores, MI
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
mi
from
St Louis, MO
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
mi
from
St Louis, MO
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
mi
from
St. Louis, MO
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
mi
from
St. Louis, MO
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
mi
from
Lincoln, NE
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
mi
from
Lincoln, NE
Click here to add this to my saved trials
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated:  8/26/2014
Clinical Research Facility
mi
from
Freehold, NJ
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056
Status: Enrolling
Updated: 8/26/2014
Clinical Research Facility
mi
from
Freehold, NJ
Click here to add this to my saved trials